CHMP2A anticorps (AA 1-100) (Cy3)

N° du produit ABIN2559692

Cet anticorps Lapin Polyclonal détecte spécifiquement CHMP2A dans WB, IF (cc) et IF (p). Il présente une réactivité envers Rat.

Aperçu rapide pour CHMP2A anticorps (AA 1-100) (Cy3) (ABIN2559692)

Antigène: CHMP2A (Charged Multivesicular Body Protein 2A (CHMP2A))

Reactivité: Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CHMP2A est conjugé à/à la Cy3

Application: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Détail du produit anti-CHMP2A anticorps (Cy3)

Épitope: AA 1-100

Réactivité croisée: Rat

Homologie: Human,Mouse,Dog,Sheep

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human CHMP2A

Isotype: IgG

Information d'application

Indications d'application: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur CHMP2A

Antigène: CHMP2A (Charged Multivesicular Body Protein 2A (CHMP2A))

Autre désignation: CHMP2A

Sujet:

Synonyms: BC2, BC-2, VPS2, CHMP2, VPS2A, Charged multivesicular body protein 2a, Chromatin-modifying protein 2a, CHMP2a, Putative breast adenocarcinoma marker BC-2, Vacuolar protein sorting-associated protein 2-1, Vps2-1, hVps2-1

Background: Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Involved in HIV-1 p6- and p9-dependent virus release.

ID gène: 27243

UniProt: O43633

Pathways: SARS-CoV-2 Protein Interactome